epidem
caus
pathogen
virus
hiv
hepat
c
viru
hcv
recent
sever
acut
respiratori
syndrom
sar
new
coronaviru
repres
major
global
health
hazard
demand
novel
broadspectrum
antivir
intervent
although
discov
year
ago
ribavirin
remain
approv
small
molecul
drug
activ
dna
rna
virus
uniqu
antivir
profil
ribavirin
deserv
brief
review
discoveri
back
two
fivememb
ring
nucleosid
antibiot
showdomycin
pyrazomycin
isol
bacteri
cultur
figur
show
signific
activ
broad
seri
virus
cell
cultur
novel
properti
nucleosid
antibiot
prompt
synthesi
test
number
imidazoleand
triazolebas
ribonucleosid
among
ribavirin
origin
term
virazol
stood
promis
broadspectrum
antivir
agent
structur
ribavirin
ribonucleosid
unconvent
triazol
base
figur
xray
crystallograph
studi
indic
fivememb
triazol
ribonucleosid
capabl
mimick
conform
sever
canon
purin
ribonucleosid
oxygen
nitrogen
spatial
eclips
atom
inosin
guanosin
rotat
bond
ribavirin
also
resembl
conform
adenosin
multipl
conform
adopt
ribavirin
make
possibl
target
viral
host
enzym
util
purin
ribonucleosidesnucleotid
substrat
cofactor
may
hold
key
broadspectrum
antivir
activ
current
data
support
notion
ribavirin
act
pleiotrop
mode
action
ribavirin
prodrug
metabol
activ
diphosph
triphosph
vivo
ribavirin
rmp
inhibit
cellular
inosin
monophosph
dehydrogenas
impdh
therebi
deplet
intracellular
pool
gtp
viral
replic
ribavirin
rtp
major
metabolit
accumul
vivo
effect
inhibitor
viral
rna
guanylyl
transferas
n
methyl
transferas
contribut
defect
structur
viral
transcript
insuffici
translat
form
ribavirin
implic
direct
inhibitor
viral
rna
polymeras
nucleotid
analogu
rtp
also
incorpor
viral
genom
induc
viru
error
catastroph
mutat
recent
studi
polioviru
replic
cell
cultur
singl
mutat
polioviru
rnadepend
rna
polymeras
shown
confer
resist
ribavirin
first
report
viral
resist
ribavirin
studi
reinforc
notion
transit
mutat
caus
incorpor
ribavirin
mutagen
respons
antivir
activ
least
case
polioviru
hand
consist
broadspectrum
antivir
properti
ribavirin
also
small
molecul
immunomodul
capabl
elicit
immunobas
antivir
activ
shift
host
immun
respons
type
therebi
enhanc
cell
mediat
immun
favour
elimin
intracellular
viral
pathogen
fact
ribavirin
resist
convincingli
identifi
clinic
set
support
notion
ribavirin
exert
effect
nonspecif
pleiotrop
mechan
despit
success
effect
antivir
cell
cultur
anim
infect
model
clinic
applic
ribavirin
far
met
mix
result
one
factor
may
limit
clinic
potenti
doselimit
haemolyt
anaemia
high
dose
administ
ribavirin
formul
small
particl
aerosol
current
approv
treatment
respiratori
syncyti
viru
rsv
infect
capsul
tablet
form
use
part
combin
therapi
chronic
hcv
infect
notabl
combin
therapi
ribavirin
nativ
pegyl
form
becom
gold
standard
antihcv
chemotherapi
treatment
hcv
infect
combin
therapi
suffer
somewhat
side
effect
haemolyt
anaemia
caus
accumul
rtp
red
blood
cell
rbc
result
dose
reduct
discontinu
therapi
proport
patient
attempt
deliv
ribavirin
specif
liver
reduc
trap
ribavirin
metabolit
rbc
therebi
improv
therapeut
index
number
ribavirin
deriv
explor
one
emerg
compound
deriv
ribavirin
viramidin
previous
known
ribamidin
see
figur
one
compound
relat
ribavirin
structureact
relationship
studi
exhibit
vitro
antivir
immunomodul
activ
compar
ribavirin
recent
biochem
pharmacokinet
studi
shown
viramidin
act
prodrug
ribavirin
differ
pharmacokinet
properti
parent
compound
possibl
result
epidem
caus
pathogen
virus
hiv
hepat
c
viru
hcv
recent
sever
acut
respiratori
syndrom
sar
new
coronaviru
repres
major
global
health
hazard
demand
novel
broadspectrum
antivir
intervent
although
discov
year
ago
ribavirin
remain
approv
small
molecul
drug
activ
dna
rna
virus
uniqu
antivir
profil
ribavirin
deserv
brief
review
discoveri
back
two
fivememb
ring
nucleosid
antibiot
showdomycin
pyrazomycin
isol
bacteri
cultur
figur
show
signific
activ
broad
seri
virus
cell
cultur
novel
properti
nucleosid
antibiot
prompt
synthesi
test
number
imidazoleand
triazolebas
ribonucleosid
among
ribavirin
origin
term
virazol
stood
promis
broadspectrum
antivir
agent
structur
ribavirin
ribonucleosid
unconvent
triazol
base
figur
xray
crystallograph
studi
indic
fivememb
triazol
ribonucleosid
capabl
mimick
conform
sever
canon
purin
ribonucleosid
oxygen
nitrogen
spatial
eclips
atom
inosin
guanosin
rotat
bond
ribavirin
also
resembl
conform
adenosin
multipl
conform
adopt
ribavirin
make
possibl
target
viral
host
enzym
util
purin
ribonucleosidesnucleotid
substrat
cofactor
may
hold
key
broadspectrum
antivir
activ
current
data
support
notion
ribavirin
act
pleiotrop
mode
action
ribavirin
prodrug
metabol
activ
diphosph
triphosph
vivo
ribavirin
rmp
inhibit
cellular
inosin
monophosph
dehydrogenas
impdh
therebi
deplet
intracellular
pool
gtp
viral
replic
ribavirin
rtp
major
metabolit
accumul
vivo
effect
inhibitor
viral
rna
guanylyl
transferas
n
methyl
transferas
contribut
defect
structur
viral
transcript
insuffici
translat
form
ribavirin
implic
direct
inhibitor
viral
rna
polymeras
nucleotid
analogu
rtp
also
incorpor
viral
genom
induc
viru
error
catastroph
mutat
recent
studi
polioviru
replic
cell
cultur
singl
mutat
polioviru
rnadepend
rna
polymeras
shown
confer
resist
ribavirin
first
report
viral
resist
ribavirin
studi
reinforc
notion
transit
mutat
caus
incorpor
ribavirin
mutagen
respons
antivir
activ
least
case
polioviru
hand
consist
broadspectrum
antivir
properti
ribavirin
also
small
molecul
immunomodul
capabl
elicit
immunobas
antivir
activ
shift
host
immun
respons
type
therebi
enhanc
cell
mediat
immun
favour
elimin
intracellular
viral
pathogen
fact
ribavirin
resist
convincingli
identifi
clinic
set
support
notion
ribavirin
exert
effect
nonspecif
pleiotrop
mechan
despit
success
effect
antivir
cell
cultur
anim
infect
model
clinic
applic
ribavirin
far
met
mix
result
one
factor
may
limit
clinic
potenti
doselimit
haemolyt
anaemia
high
dose
administ
ribavirin
formul
small
particl
aerosol
current
approv
treatment
respiratori
syncyti
viru
rsv
infect
capsul
tablet
form
use
part
combin
therapi
chronic
hcv
infect
notabl
combin
therapi
ribavirin
nativ
pegyl
form
becom
gold
standard
antihcv
chemotherapi
treatment
hcv
infect
combin
therapi
suffer
somewhat
side
effect
haemolyt
anaemia
caus
accumul
rtp
red
blood
cell
rbc
result
dose
reduct
discontinu
therapi
proport
patient
attempt
deliv
ribavirin
specif
liver
reduc
trap
ribavirin
metabolit
rbc
therebi
improv
therapeut
index
number
ribavirin
deriv
explor
one
emerg
compound
deriv
ribavirin
viramidin
previous
known
ribamidin
see
figur
one
compound
relat
ribavirin
structureact
relationship
studi
exhibit
vitro
antivir
immunomodul
activ
compar
ribavirin
recent
biochem
pharmacokinet
studi
shown
viramidin
act
prodrug
ribavirin
differ
pharmacokinet
properti
parent
compound
possibl
result
anim
studi
indic
viramidin
better
liver
target
properti
ribavirin
liver
thought
main
convers
site
prodrug
illustr
quantit
whole
bodi
autoradiographi
rat
figur
radiolabel
drug
trap
liver
oral
dose
c
viramidin
compar
c
ribavirin
studi
monkey
suggest
viramidin
yield
three
time
drug
liver
half
drug
level
rbc
compar
ribavirin
preferenti
liver
target
properti
concomit
reduct
haemolyt
potenti
viramidin
appear
safe
altern
ribavirin
may
provid
mani
clinic
benefit
hcv
patient
current
phase
ii
clinic
trial
activ
chronic
hcv
infect
understand
metabol
convers
viramidin
ribavirin
gain
knowledg
prodrug
design
investig
enzym
mechan
viramidin
deamin
base
structur
similar
viramidin
adenosin
adenosin
deaminas
ada
believ
potenti
enzym
catalys
convers
ada
catalys
hydrolyt
deamin
adenosin
inosin
ammonia
key
enzym
purin
metabol
ubiquit
present
virtual
mammalian
tissu
critic
immun
compet
use
uv
spectroscop
method
discov
ada
inde
catalys
convers
viramidin
ribavirin
vitro
enzym
reaction
catalyt
effici
mm
pb
buffer
ph
interestingli
shift
buffer
ph
catalyt
effici
increas
mm
k
mm
k
cat
compar
deamin
adenosin
reaction
unusu
high
optim
ph
optim
ph
coincid
pk
viramidin
impli
viramidin
first
undergo
deproton
deamin
previou
studi
report
ribavirin
deamin
vivo
carboxyl
deriv
metabolit
possess
antivir
activ
figur
therefor
investig
possibl
ada
catalys
anoth
round
deamin
convert
ribavirin
deamin
slow
catalyt
effici
mm
optim
ph
although
studi
rule
particip
enzym
metabol
viramidin
nevertheless
suggest
ada
strong
candid
convers
vivo
experi
also
reveal
unusu
propens
ada
catalys
two
consecut
deamin
reaction
singl
substrat
first
thick
section
prepar
use
lkbmicrotom
expos
highli
sensit
film
day
major
organstissu
identifi
section
respect
radioact
content
measur
quantit
use
computer
densitometri
colour
imag
red
densiti
reflect
amount
radioact
section
clearli
liver
enrich
much
drug
viramidinetr
rat
ribavirintr
rat
hydrolys
viramidin
slowli
convert
ribavirin
inact
metabolit
figur
enzymeactiv
prodrug
approach
strategi
wide
employ
improv
absorpt
bioavail
target
specif
potenti
therapeut
agent
order
minim
advers
side
effect
ada
ideal
enzym
prodrug
activ
ubiquit
presenc
human
tissu
enorm
catalyt
capabl
inde
mani
exampl
adaactiv
purin
nucleosid
prodrug
report
figur
exampl
prodrug
antiherpet
aciclovir
report
improv
absorpt
gut
attain
higher
plasma
level
similarli
deriv
fddi
ddi
prepar
acidst
prodrug
central
nervou
deliveri
dioxolan
current
clinic
trial
watersolubl
bioavail
prodrug
guanin
dioxolan
treatment
hiv
infect
design
enhanc
system
central
nervou
system
deliveri
howev
prodrug
base
base
convert
inosin
guanosin
ada
figur
viramidin
exampl
adaactiv
prodrug
possess
noncogn
fivememb
triazol
base
place
purin
enzymeactiv
prodrug
good
substrat
order
effici
convert
activ
form
mechan
substrat
specif
adacatalys
deamin
comprehend
atom
level
cocryst
structur
ada
complex
transitionst
analogu
ribonucleosid
hdpr
model
adenosin
replac
hdpr
activ
site
ground
state
adenosin
bind
exampl
adaactiv
prodrug
includ
dioxolan
c
specif
interact
adenosin
ada
activ
site
adenosin
model
replac
hdpr
ada
activ
site
base
publish
cocryst
structur
ada
complex
hdpr
ada
visual
figur
evid
ada
initi
hydrolyt
deamin
asp
act
gener
base
assist
zincbound
water
molecul
nucleophil
attack
posit
adenosin
substrat
recognit
command
nonspecif
hydrophob
interact
well
specif
interact
adenosin
purin
ring
form
three
individu
hydrogen
bond
activesit
residu
glu
gli
asp
respect
figur
among
first
interact
believ
critic
catalysi
latter
two
import
substrat
recognit
bind
affin
convers
ribos
form
direct
interact
enzym
group
ribos
interact
order
activesit
water
molecul
addit
form
hydrogen
bond
asp
sinc
dideoxi
ribonucleosid
util
substrat
ada
three
hydrogen
bond
like
insignific
substrat
recognit
howev
appear
play
key
role
ribos
recognit
sinc
interact
asp
hydrogen
bond
figur
base
structur
analysi
ada
toler
major
structur
alter
ribos
less
purin
design
sound
prodrug
three
specif
hydrogen
bond
purin
two
preserv
conclus
consist
structur
featur
known
prodrug
illustr
figur
b
known
prodrug
intact
purin
equival
group
adaactiv
prodrug
viramidin
one
miss
critic
hydrogen
bond
explain
high
k
valu
viramidin
nevertheless
fact
viramidin
adaactiv
prodrug
suggest
possibl
design
prodrug
employ
noncogn
fivememb
ring
base
place
purin
provid
critic
interact
conserv
avail
much
biochem
structur
inform
ada
rel
straightforward
design
adaactiv
nucleosid
prodrug
howev
first
daunt
task
discov
broadspectrum
antivir
nucleosid
first
place
compar
pervas
nucleotid
prodrug
design
focus
modif
vivo
deliveri
adaactiv
prodrug
possess
novel
pharmacokinet
properti
verif
adacatalys
viramidin
convers
ribavirin
open
new
chapter
design
novel
organspecif
adaactiv
nucleosid
prodrug
antivir
anticanc
chemotherapi
